HONG KONG, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ:PASW) (the "Company") today announced that it has entered into a definitive purchase agreement (the "Agreement") with
HONG KONG, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ:PASW) (the "Company") today announced its entry into a letter of intent with Future Biotechnology Group Co., Limited (the
HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ:PASW) ("Ping An Bio" or the "Company") announced that its board of directors has approved a 1-for-40 reverse stock
HONG KONG, July 22, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ:PASW) (hereinafter referred to as "Ping An Biomedical") announced that it has formally signed a strategic cooperation agreement
HONG KONG, March 19, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ:PASW) (hereinafter referred to as "Ping An Bio") announced that shareholders have approved all five resolutions at the company's 2026
HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ:PASW) (hereinafter referred to as "Ping An Bio") announced that it has entered into a non-binding memorandum (the "Investment
HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ:PASW) (hereinafter referred to as "Ping An Bio") today announced that it has entered into a series of share purchase agreements with
Hong Kong, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ:PASW) (the "Company") today announced receipt of Nasdaq Minimum Bid Price Deficiency Letter. On November 24, 2025, Ping An Biomedical
